Related Experiment Video
Updated: May 9, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Genetics of ankylosing spondylitis
Philip C Robinson1, Matthew A Brown
1University of Queensland Diamantina Institute, Translational Research Institute, 37 Kent Road, Princess Alexandra Hospital, Brisbane, Australia.
Ankylosing spondylitis (AS) is a chronic inflammatory disease impacting the spine. Recent genetic research has significantly advanced understanding and led to new treatment trials.
Area of Science:
- Rheumatology and Immunology
- Genetics and Pathogenesis
Background:
- Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the axial skeleton.
- AS is linked to significant disability and extra-articular manifestations like uveitis and inflammatory bowel disease (IBD).
Purpose of the Study:
- To summarize recent advancements in the understanding of AS aetiopathogenesis.
- To highlight progress in AS genetics and its implications for new therapeutic strategies.
Main Methods:
- Review of recent genetic studies in ankylosing spondylitis.
- Analysis of emerging data on AS pathogenesis.
- Evaluation of ongoing clinical trials for novel AS treatments.
Main Results:
- Substantial progress in identifying genetic factors contributing to AS.
- Enhanced understanding of the molecular mechanisms underlying AS development.
- Identification of promising new therapeutic targets and treatments in clinical trials.
Conclusions:
- Recent genetic discoveries have revolutionized the understanding of AS.
- These advancements are paving the way for more effective and targeted therapies for ankylosing spondylitis.
- Further research into AS pathogenesis holds promise for improved patient outcomes.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
The JAK-STAT Signaling Pathway
Inflammatory Bowel Disease III: Crohn's Disease
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Incomplete Dominance
